Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Fungal Phylum Microsporidia

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity.

Advances in therapy·2026

Same author

Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries.

The Lancet. Respiratory medicine·2026

Same author

Safety and effectiveness of benralizumab in Indian patients with severe eosinophilic asthma: results from the FAST study.

Frontiers in medicine·2026

Same author

Corrigendum to: A Comprehensive Review on Deep Learning Techniques in Alzheimer's Disease Diagnosis.

Current topics in medicinal chemistry·2026

Same author

Understanding disease burden, challenges in current treatment strategies and call for action for management of severe asthma in Asia: a position statement from Asian respiratory experts.

Frontiers in allergy·2026

Same author

Development and validation of the Hypersensitivity Pneumonitis South Asian Questionnaire for Exposure (HP-SAQE): a novel, qualitative and quantitative tool.

Thorax·2026

Search research articles

Related Experiment Video

Updated: May 11, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Echinocandins in invasive candidiasis.

John Simon¹, Hsin-Yun Sun, Hoe Nam Leong

¹University of Hong Kong, Pokfulam, Hong Kong, China.

|May 8, 2013

Summary

Echinocandins show efficacy and a favorable safety profile for invasive candidiasis (IC) management. They are well-tolerated, especially in vulnerable patient groups, and offer fewer drug interactions than azoles.

Keywords:

Echinocandins candidaemia critically ill

More Related Videos

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Related Experiment Videos

Last Updated: May 11, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Area of Science:

Infectious Diseases
Pharmacology
Clinical Medicine

Background:

Invasive candidiasis (IC) poses a significant clinical challenge, particularly with rising azole-resistant non-albicans strains.
Current treatment guidelines require careful consideration of drug interactions and patient-specific factors.

Framework:

Echinocandins exhibit potent antifungal activity against a broad spectrum of Candida species, including azole-resistant isolates.
Clinical trials and expert experience highlight the efficacy of echinocandins in treating IC.

Implementation:

Echinocandins are well-tolerated across diverse inpatient populations, including transplant recipients and patients with renal or hepatic impairment.
Their favorable safety profile minimizes adverse events and simplifies management in complex cases.

Implications:

Echinocandins offer a favorable safety profile with minimal drug-drug interactions, contrasting with oral azoles.
Due to increasing azole resistance, echinocandins are emerging as a potential first-line treatment for invasive candidiasis.